AxoGen, Inc (NASDAQ:AXGN) Director Quentin S. Blackford acquired 15,535 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average price of $14.01 per share, with a total value of $217,645.35. Following the transaction, the director now directly owns 25,098 shares in the company, valued at $351,622.98. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.
AXGN stock opened at $14.60 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.70 and a quick ratio of 7.87. The company has a 50 day moving average price of $18.15 and a 200 day moving average price of $19.82. AxoGen, Inc has a fifty-two week low of $11.82 and a fifty-two week high of $46.25. The stock has a market capitalization of $599.82 million, a PE ratio of -27.04 and a beta of 0.18.
AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.09. AxoGen had a negative net margin of 26.91% and a negative return on equity of 16.73%. The firm had revenue of $26.70 million during the quarter, compared to analysts’ expectations of $26.77 million. During the same quarter in the previous year, the company posted ($0.09) EPS. AxoGen’s revenue was up 29.7% on a year-over-year basis. As a group, equities analysts expect that AxoGen, Inc will post -0.72 earnings per share for the current fiscal year.
AXGN has been the subject of several research analyst reports. BTIG Research dropped their price objective on shares of AxoGen to $21.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. William Blair cut shares of AxoGen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 7th. Canaccord Genuity set a $30.00 price objective on shares of AxoGen and gave the stock a “buy” rating in a research report on Wednesday, August 7th. BidaskClub upgraded shares of AxoGen from a “strong sell” rating to a “sell” rating in a research report on Friday. Finally, ValuEngine upgraded shares of AxoGen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $31.00.
AxoGen Company Profile
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.